RGEN Repligen Corp

Price (delayed)

$190.14

Market cap

$10.44B

P/E Ratio

127.61

Dividend/share

N/A

EPS

$1.49

Enterprise value

$10.01B

Repligen is an American company devoted to the development and production of materials used in the manufacture of biological drugs. The company is based in Waltham, Massachusetts, and incorporated in ...

Highlights
RGEN's gross profit has soared by 54% YoY and by 19% QoQ
The revenue has soared by 52% YoY and by 18% from the previous quarter
RGEN's quick ratio has dropped by 82% year-on-year but it is up by 3.6% since the previous quarter
The debt has grown by 5% YoY

Key stats

What are the main financial stats of RGEN
Market
Shares outstanding
54.9M
Market cap
$10.44B
Enterprise value
$10.01B
Valuations
Price to earnings (P/E)
127.61
Price to book (P/B)
6.69
Price to sales (P/S)
24.07
EV/EBIT
106.57
EV/EBITDA
81.35
EV/Sales
23.11
Earnings
Revenue
$433.01M
EBIT
$93.91M
EBITDA
$123.03M
Free cash flow
$31.98M
Per share
EPS
$1.49
Free cash flow per share
$0.58
Book value per share
$28.41
Revenue per share
$7.9
TBVPS
$18.76
Balance sheet
Total assets
$1.93B
Total liabilities
$371.11M
Debt
$279.89M
Equity
$1.56B
Working capital
$613.01M
Liquidity
Debt to equity
0.18
Current ratio
2.96
Quick ratio
2.56
Net debt/EBITDA
-3.51
Margins
EBITDA margin
28.4%
Gross margin
57.4%
Net margin
18.4%
Operating margin
21.8%
Efficiency
Return on assets
4.7%
Return on equity
6%
Return on invested capital
26.9%
Return on capital employed
5.8%
Return on sales
21.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

RGEN stock price

How has the Repligen stock price performed over time
Intraday
0.26%
1 week
2.1%
1 month
10.57%
1 year
62.87%
YTD
-0.78%
QTD
-2.2%

Financial performance

How have Repligen's revenue and profit performed over time
Revenue
$433.01M
Gross profit
$248.61M
Operating income
$94.3M
Net income
$79.56M
Gross margin
57.4%
Net margin
18.4%
The operating income has soared by 156% YoY and by 35% from the previous quarter
The net margin has soared by 127% YoY and by 12% from the previous quarter
The operating margin has soared by 69% YoY and by 14% from the previous quarter
RGEN's gross profit has soared by 54% YoY and by 19% QoQ

Growth

What is Repligen's growth rate over time

Valuation

What is Repligen stock price valuation
P/E
127.61
P/B
6.69
P/S
24.07
EV/EBIT
106.57
EV/EBITDA
81.35
EV/Sales
23.11
RGEN's EPS is up by 31% since the previous quarter
The stock's P/E is 26% below its last 4 quarters average of 172.4
Repligen's equity has increased by 45% YoY
The P/B is 34% more than the 5-year quarterly average of 5.0
RGEN's P/S is 60% above its 5-year quarterly average of 15.0
The revenue has soared by 52% YoY and by 18% from the previous quarter

Efficiency

How efficient is Repligen business performance
The return on equity has surged by 161% year-on-year and by 20% since the previous quarter
RGEN's ROA has soared by 161% year-on-year and by 24% since the previous quarter
The ROIC has soared by 147% YoY and by 45% from the previous quarter
RGEN's return on sales has surged by 68% year-on-year and by 11% since the previous quarter

Dividends

What is RGEN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RGEN.

Financial health

How did Repligen financials performed over time
RGEN's quick ratio has dropped by 82% year-on-year but it is up by 3.6% since the previous quarter
Repligen's current ratio has shrunk by 81% YoY but it has increased by 4.6% QoQ
The debt is 82% less than the equity
Repligen's equity has increased by 45% YoY
Repligen's debt to equity has decreased by 28% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.